Pediatric Acute Leukemia (PedAL) Screening Trial

Summary

This clinical trial aims to use clinical and biological characteristics of acute leukemias to screen patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient’s leukemia that is important when deciding how best to treat it, and it may help doctors find better ways to diagnose and treat leukemias in children, adolescents, and young adults. 

COG # APAL2020SC

To be included in PedAL, participants must be / have

• Patient must be less than 22 years of age at time of study enrollment
• Patient must have one of the following: 
  • Known or suspected relapsed/refractory (including primary refractory) AML
    • This includes isolated myeloid sarcoma
  • Known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome
• Patient has known or suspected relapsed ALL that meets one of the following criteria:
  • Second or greater B-ALL medullary relapse, excluding KMT2Ar
  • Any first or greater B-ALL medullary relapse involving KMT2Ar
  • Any first or greater T-ALL medullary relapse with or without KMT2Ar
• Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia
• Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment related AML
• Patient has known or suspected de novo or relapsed/refractory (including primary refractory) myelodysplastic syndrome (MDS)
• Patient has known or suspected de novo or relapsed/refractory (including primary refractory) juvenile myelomonocytic leukemia (JMML)
• All patients/guardians must sign a written informed consent

To be included in PedAL, participants must not be / have

• There is no exclusion criteria for this study

Keywords

Leukemia